Ad Header



The Pulse of the Pharmaceutical Industry

Roche’s Perjeta regimen gets FDA priority review

Written by: | | Dated: Friday, September 29th, 2017


Roche’s Perjeta regimen gets FDA priority review in breast cancer


ZURICH (Reuters) – The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.

The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.

A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines.


Reporting by Michael Shields


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom